37
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Nuclear entry and egress of parvoviruses

      review-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Parvoviruses are small non‐enveloped single‐stranded DNA viruses, which depend on host cell nuclear transcriptional and replication machinery. After endosomal exposure of nuclear localization sequence and a phospholipase A 2 domain on the capsid surface, and escape into the cytosol, parvovirus capsids enter the nucleus. Due to the small capsid diameter of 18–26 nm, intact capsids can potentially pass into the nucleus through nuclear pore complexes (NPCs). This might be facilitated by active nuclear import, but capsids may also follow an alternative entry pathway that includes activation of mitotic factors and local transient disruption of the nuclear envelope. The nuclear entry is followed by currently undefined events of viral genome uncoating. After genome release, viral replication compartments are initiated and infection proceeds. Parvoviral genomes replicate during cellular S phase followed by nuclear capsid assembly during virus‐induced S/G2 cell cycle arrest. Nuclear egress of capsids occurs upon nuclear envelope degradation during apoptosis and cell lysis. An alternative pathway for nuclear export has been described using active transport through the NPC mediated by the chromosome region maintenance 1 protein, CRM1, which is enhanced by phosphorylation of the N‐terminal domain of VP2. However, other alternative but not yet uncharacterized nuclear export pathways cannot be excluded.

          Abstract

          Parvovirus capsids enter the nucleus by active import or by an alternative entry pathway that includes local transient disruption of the nuclear envelope. Parvoviral genomes replicate during cellular S phase followed by nuclear capsid assembly. The egress of progeny capsids occurs upon nuclear envelope degradation during cell lysis or by using active transport through the nuclear pore complexes.

          Related collections

          Most cited references173

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Current Clinical Applications of In Vivo Gene Therapy with AAVs

          Hereditary diseases are caused by mutations in genes, and more than 7,000 rare diseases affect over 30 million Americans. For more than 30 years, hundreds of researchers have maintained that genetic modifications would provide effective treatments for many inherited human diseases, offering durable and possibly curative clinical benefit with a single treatment. This review is limited to gene therapy using adeno-associated virus (AAV) because the gene delivered by this vector does not integrate into the patient genome and has a low immunogenicity. There are now five treatments approved for commercialization and currently available, i.e., Luxturna, Zolgensma, the two chimeric antigen receptor T cell (CAR-T) therapies (Yescarta and Kymriah), and Strimvelis (the gammaretrovirus approved for adenosine deaminase-severe combined immunodeficiency [ADA-SCID] in Europe). Dozens of other treatments are under clinical trials. The review article presents a broad overview of the field of therapy by in vivo gene transfer. We review gene therapy for neuromuscular disorders (spinal muscular atrophy [SMA]; Duchenne muscular dystrophy [DMD]; X-linked myotubular myopathy [XLMTM]; and diseases of the central nervous system, including Alzheimer’s disease, Parkinson’s disease, Canavan disease, aromatic l-amino acid decarboxylase [AADC] deficiency, and giant axonal neuropathy), ocular disorders (Leber congenital amaurosis, age-related macular degeneration [AMD], choroideremia, achromatopsia, retinitis pigmentosa, and X-linked retinoschisis), the bleeding disorder hemophilia, and lysosomal storage disorders.
            • Record: found
            • Abstract: not found
            • Article: not found

            The clinical landscape for AAV gene therapies

              • Record: found
              • Abstract: found
              • Article: not found

              Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

              The human parvovirus adeno-associated virus (AAV) infects a broad range of cell types, including human, nonhuman primate, canine, murine, and avian. Although little is known about the initial events of virus infection, AAV is currently being developed as a vector for human gene therapy. Using defined mutant CHO cell lines and standard biochemical assays, we demonstrate that heparan sulfate proteoglycans mediate both AAV attachment to and infection of target cells. Competition experiments using heparin, a soluble receptor analog, demonstrated dose-dependent inhibition of AAV attachment and infection. Enzymatic removal of heparan but not chondroitin sulfate moieties from the cell surface greatly reduced AAV attachment and infectivity. Finally, mutant cell lines that do not produce heparan sulfate proteoglycans were significantly impaired for both AAV binding and infection. This is the first report that proteoglycan has a role in cellular attachment of a parvovirus. Together, these results demonstrate that membrane-associated heparan sulfate proteoglycan serves as the viral receptor for AAV type 2, and provide an explanation for the broad host range of AAV. Identification of heparan sulfate proteoglycan as a viral receptor should facilitate development of new reagents for virus purification and provide critical information on the use of AAV as a gene therapy vector.

                Author and article information

                Contributors
                michael.kann@gu.se
                maija.vihinen-ranta@jyu.fi
                Journal
                Mol Microbiol
                Mol Microbiol
                10.1111/(ISSN)1365-2958
                MMI
                Molecular Microbiology
                John Wiley and Sons Inc. (Hoboken )
                0950-382X
                1365-2958
                24 August 2022
                October 2022
                : 118
                : 4 , Special Section: Nuclear Entry of Viruses ( doiID: 10.1111/mmi.v118.4 )
                : 295-308
                Affiliations
                [ 1 ] Department of Biological and Environmental Science University of Jyvaskyla Jyvaskyla Finland
                [ 2 ] Department of Infectious Diseases, Institute of Biomedicine University of Gothenburg Gothenburg Sweden
                [ 3 ] Sahlgrenska Academy Gothenburg Sweden
                [ 4 ] Department of Clinical Microbiology Region Västra Götaland, Sahlgrenska University Hospital Gothenburg Sweden
                Author notes
                [*] [* ] Correspondence

                Michael Kann, Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.

                Email: michael.kann@ 123456gu.se

                Maija Vihinen‐Ranta, Department of Biological and Environmental Science, University of Jyvaskyla, PO Box 35, 40014 Jyvaskyla, Finland.

                Email: maija.vihinen-ranta@ 123456jyu.fi

                Author information
                https://orcid.org/0000-0003-0959-1153
                Article
                MMI14974 MMI-2022-18964.R1
                10.1111/mmi.14974
                9805091
                35974704
                f3349958-b204-4f48-a06c-c4d6068b7eee
                © 2022 The Authors. Molecular Microbiology published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 10 August 2022
                : 23 May 2022
                : 13 August 2022
                Page count
                Figures: 4, Tables: 2, Pages: 14, Words: 10784
                Funding
                Funded by: Academy of Finland , doi 10.13039/501100002341;
                Award ID: 330896
                Funded by: Graduate School of the University of Jyvaskyla
                Award ID: 2022
                Funded by: Jane ja Aatos Erkon Säätiö , doi 10.13039/501100004012;
                Award ID: 2019
                Categories
                Micro Review
                Special Section: Nuclear Entry of Viruses
                Custom metadata
                2.0
                October 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.3 mode:remove_FC converted:31.12.2022

                Microbiology & Virology
                import and export,nuclear envelope,nuclear pore complexes,nucleus,parvoviruses

                Comments

                Comment on this article

                Related Documents Log